top
Please input keywords
Order
*Country
United States
China
France
Germany
Netherlands
United Kingdom
Japan
South Korea
Israel
Australia
Hong Kong, China
New Zealand
Russia
Singapore
Taiwan, China
India
Aland Islands
Albania
Algeria
American Samoa
Andorra
Angola
Anguilla
Antarctica
Antigua & Barbuda
Argentina
Armenia
Aruba
Ascension Island
Austria
Azerbaijan
Bahamas
Bahrain
Bangladesh
Barbados
Belarus
Belgium
Belize
Benin
Bermuda
Bhutan
Bolivia
Bosnia & Herzegovina
Botswana
Brazil
British Indian Ocean Territory
British Virgin Islands
Brunei
Bulgaria
Burkina Faso
Burundi
Cambodia
Cameroon
Canada
Canary Islands
Cape Verde
Caribbean Netherlands
Cayman Islands
Central African Republic
Ceuta & Melilla
Chad
Chile
Christmas Island
Cocos (Keeling) Islands
Colombia
Comoros
Congo - Brazzaville
Congo - Kinshasa
Cook Islands
Costa Rica
Côte d’Ivoire
Croatia
Cuba
Curaçao
Cyprus
Czechia
Denmark
Diego Garcia
Djibouti
Dominica
Dominican Republic
Ecuador
Egypt
El Salvador
Equatorial Guinea
Eritrea
Estonia
Ethiopia
Falkland Islands
Faroe Islands
Fiji
Finland
French Guiana
French Polynesia
French Southern Territories
Gabon
Gambia
Georgia
Ghana
Gibraltar
Greece
Greenland
Grenada
Guadeloupe
Guam
Guatemala
Guernsey
Guinea
Guinea-Bissau
Guyana
Haiti
Honduras
Hungary
Iceland
Indonesia
Iran
Iraq
Ireland
Isle of Man
Italy
Jamaica
Jersey
Jordan
Kazakhstan
Kenya
Kiribati
Kosovo
Kuwait
Kyrgyzstan
Laos
Latvia
Lebanon
Lesotho
Liberia
Libya
Liechtenstein
Lithuania
Luxembourg
Macau, China
Macedonia
Madagascar
Malawi
Malaysia
Maldives
Mali
Malta
Marshall Islands
Martinique
Mauritania
Mauritius
Mayotte
Mexico
Micronesia
Moldova
Monaco
Mongolia
Montenegro
Montserrat
Morocco
Mozambique
Myanmar (Burma)
Namibia
Nauru
Nepal
New Caledonia
Nicaragua
Niger
Nigeria
Niue
Norfolk Island
North Korea
Northern Mariana Islands
Norway
Oman
Pakistan
Palau
Palestinian Territories
Panama
Papua New Guinea
Paraguay
Peru
Philippines
Pitcairn Islands
Poland
Portugal
Puerto Rico
Qatar
Réunion
Romania
Rwanda
Samoa
San Marino
São Tomé & Príncipe
Saudi Arabia
Senegal
Serbia
Seychelles
Sierra Leone
Sint Maarten
Slovakia
Slovenia
Solomon Islands
Somalia
South Africa
South Georgia & South Sandwich Islands
South Sudan
Spain
Sri Lanka
St. Barthélemy
St. Helena
St. Kitts & Nevis
St. Lucia
St. Martin
St. Pierre & Miquelon
St. Vincent & Grenadines
Sudan
Suriname
Svalbard & Jan Mayen
Swaziland
Sweden
Switzerland
Syria
Tajikistan
Tanzania
Thailand
Timor-Leste
Togo
Tokelau
Tonga
Trinidad & Tobago
Tristan da Cunha
Tunisia
Turkey
Turkmenistan
Turks & Caicos Islands
Tuvalu
U.S. Outlying Islands
U.S. Virgin Islands
Uganda
Ukraine
United Arab Emirates
United Nations
Uruguay
Uzbekistan
Vanuatu
Vatican City
Venezuela
Vietnam
Wallis & Futuna
Western Sahara
Yemen
Zambia
Zimbabwe
*Province
*City
*Name
*Telephone
*Company
*Position
*Email
*Verification code
*Verification Code
B-hIL6/hIL6R mice
Strain Name
C57BL/6-Il6tm1(IL6)BcgenIl6rtm2(IL6R)Bcgen/Bcgen
Common Name  B-hIL6/hIL6R mice
Background C57BL/6 Catalog number  120557
Related Genes 
IL6: CDF; HGF; HSF; BSF2; IL-6; BSF-2; IFNB2; IFN-beta-2
IL6R: IL6Q; gp80; CD126; IL6RA; IL6RQ; IL-6RA; IL-6R-1
NCBI Gene ID
16193,16194

mRNA expression analysis

from clipboard


Strain specific analysis of IL6 and IL6R gene expression in B-hIL6/hIL6R mice by RT-PCR. Mouse Il6 and Il6r mRNA were detectable in spleen of wild-type mice (+/+). Human IL6 was detectable only in homozygous B-hIL6/hIL6R mice (H/H) after stimulated with LPS for 3h. Human IL6R mRNA was detectable in homozygous B-hIL6/hIL6R mice but not in wild-type mice with or without LPS stimulation.


Protein expression analysis

from clipboard


Strain specific IL6 expression analysis in homozygous B-hIL6/hIL6R mice by ELISA. 
Serum were collected from WT (+/+) and homozygous B-hIL6/hIL6R (H/H) mice stimulated with LPS in vivo, and analyzed by ELISA with species-specific IL6 ELISA kit. Mouse Il6 was detectable in WT mice. Human IL6 was exclusively detectable in homozygous B-hIL6/hIL6R mice but not in WT mice.


Protein expression analysis

from clipboard

Strain specific IL6R expression analysis in homozygous B-hIL6/hIL6R mice by flow cytometry. Splenocytes were collected from WT (+/+) and homozygous B-hIL6/hIL6R mice (H/H), and analyzed by flow cytometry with species-specific anti-IL6R antibody. Mouse IL6R was detectable in WT mice. Human IL6R was exclusively detectable in homozygous B-hIL6/hIL6R mice but not in WT mice.


IL6R expression pattern analysis by IHC


from clipboard


Representative human IL6R expression in different tissues of B-hIL6/IL6R mice by IHC. Tissues were collected from homozygous B-hIL6/hIL6R mice and stained with antibodies for human IL6R (A-I) or anti-IgG antibodies (J). Human tonsils as positive control (I); Mouse lung stained with anti-IgG antibodies as a negative control (J); As shown in the figure, human IL6R was detected in brain, colon, kidney, liver, lung, spleen and thymus, but not in heart. Original magnification ×200. Abbreviations: IHC, immunohistochemistry. 


Protein expression analysis in plasma


from clipboard

Strain specific IL6R expression analysis in wild-type C57BL/6 mice and homozygous humanized B-hIL6/IL6R mice by ELISA. Plasma(EDTA) was collected from wild-type C57BL/6 mice (female, 6-week-old, n=3) and homozygous B-hIL6/IL6R mice (female, 6-week-old, n=3). Expression level of human IL6R were analyzed by ELISA (human IL6R ELISA kit: R&D, DR600). Human IL6R was exclusively detectable in homozygous B-hIL6/IL6R mice. Values are expressed as mean ± SEM.


Protein expression analysis

from clipboard

Soluble human IL6R expression analysis in homozygous B-hIL6/hIL6R mice by ELISA. Liver and pancreas were isolated from wild-type C57BL/6 mice (female, 7-week-old, n=3) and homozygous B-hIL6/hIL6R mice (female, 7-week-old, n=3), and analyzed by ELISA with species-specific anti-human IL6R ELISA kit (human IL6R ELISA kit: R&D, DR600). Soluble human IL6R was detectable in liver (A) and pancreas (B) of homozygous B-hIL6/hIL6R mice but not in wild-type mice.

In vivo efficacy of anti-human IL6 antibody

from clipboard

Efficacy of anti-human IL6 antibodies in B-hIL6/hIL6R mice with collagen induced arthritis (CIA) model. Mice in each group were treated with sirukumab (in house). Body weight change(A) and clinical score (B) were evaluated during treatment twice a week. There was no significant change in body weight, while total clinical score increased in the groups except control during days 21 to 28. It indicated that the arthritis mouse model had been constructed successfully. Clinical scores decreased in the two groups treated with sirukumab and dose-dependent. The results indicated the B-hIL6/hIL6R mice provide a powerful preclinical model for in vivo evaluation of anti-human IL6 antibodies.

In vivo efficacy of anti-human IL6 antibody


from clipboard

from clipboard


Efficacy of anti-human IL6 antibody in B-hIL6/hIL6R mice with collagen induced arthritis (CIA) model. Histopathological examination was performed on the joints of the extremities at endpoint. (A) Hematoxylin and eosin (H&E) staining. (B) Score of arthritis histology. G1 showed no significant abnormal changes. G2 showed bone structure damage(d), articular cavity or periarticular space disappeared (e), and pannus were observed (a), suggesting that the CIA model was successfully established. Compared with the G2 group, the low-dose group (G3) showed slight inflammatory cell infiltration (b) and pannus (a) and synovial hyperplasia (c). However, in the high dose group (G4), there was only partial pannus, the arthrosis disappeared and the articular cavity was obvious.



Analysis of spleen leukocytes cell subpopulations in B-hIL6/hIL6R mice


from clipboard



from clipboard


Analysis of spleen leukocyte subpopulations by FACS. Splenocytes were isolated from female C57BL/6 and B-hIL6/hIL6R mice (n=3, 6-week-old). Flow cytometry analysis of the splenocytes were performed to assess leukocyte subpopulations. (A) Representative FACS plots. Single live cells were gated for the CD45+ population and used for further analysis as indicated here. (B) Results of FACS analysis. Percent of T cell, B cell, NK cell, monocyte, dendritic cell and macrophage in homozygous B-hIL6/hIL6R mice were similar to those in the C57BL/6 mice, demonstrating that IL6 and IL6R humanized does not change the overall development, differentiation or distribution of these cell types in spleen. Values are expressed as mean ± SEM.


Analysis of spleen T cell subpopulations in B-hIL6/hIL6R mice


from clipboard


Analysis of spleen T cell subpopulations by FACS. Splenocytes were isolated from female C57BL/6 and B-hIL6/hIL6R mice (n=3, 6-week-old).  Flow cytometry analysis of the splenocytes were performed to assess leukocyte subpopulations. (A) Representative FACS plots. Single live CD45+ cells were gated for CD3+ T cell population and used for further analysis as indicated here. (B) Results of FACS analysis. Percent of CD8+ T cell, CD4+ T cell, and Treg in homozygous B-hIL6/hIL6R mice were similar to those in the C57BL/6 mice, demonstrating that IL6 and IL6R humanized does not change the overall development, differentiation or distribution of these cell types in spleen. Values are expressed as mean ± SEM.

Analysis of lymph node leukocytes cell subpopulations in B-hIL6/hIL6R mice

from clipboard


Analysis of lymph node leukocyte subpopulations by FACS. Leukocytes were isolated from female C57BL/6 and B-hIL6/hIL6R mice (n=3, 6-week-old) Flow cytometry analysis of the leukocytes was performed to assess leukocyte subpopulations. (A) Representative FACS plots. Single live cells were gated for the CD45+ population and used for further analysis as indicated here. (B)  Results of FACS analysis. Percent of T cell, B cell and NK cell in homozygous B-hIL6/hIL6R mice were similar to those in the C57BL/6 mice, demonstrating that introduction of hIL6/hIL6R in place of its mouse counterpart does not change the overall development, differentiation or distribution of these cell types in lymph node. Values are expressed as mean ± SEM.

Analysis of lymph node T cell subpopulations in B-hIL6/hIL6R mice

from clipboard


Analysis of lymph node T cell subpopulations by FACS. Leukocytes were isolated from female C57BL/6 and B-hIL6/hIL6R mice (n=3, 6 week-old).  Flow cytometry analysis of the leukocytes was performed to assess leukocyte subpopulations. (A) Representative FACS plots. Single live CD45+ cells were gated for CD3 T cell population and used for further analysis as indicated here. (B) Results of FACS analysis. Percent of CD8+ cell, CD4+ cell, and Treg in homozygous B-hIL6/hIL6R mice were similar to those in the C57BL/6 mice, demonstrating that IL6 and IL6R humanized does not change the overall development, differentiation or distribution of these T cell subtypes in lymph node. Values are expressed as mean ± SEM.